Richard M. Glickman - Oct 31, 2023 Form 4 Insider Report for enGene Holdings Inc. (ENGN)

Role
Director
Signature
/s/ Richard Glickman
Stock symbol
ENGN
Transactions as of
Oct 31, 2023
Transactions value $
$0
Form type
4
Date filed
11/2/2023, 04:08 PM
Previous filing
Nov 1, 2022
Next filing
Mar 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENGN Common Shares Award +24.6K 24.6K Oct 31, 2023 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENGN Stock Option (Right to Buy) Award +120 120 Dec 4, 2013 Common Shares 120 $0.88 Direct F1, F2, F4
transaction ENGN Stock Option (Right to Buy) Award +11.2K 11.2K May 21, 2015 Common Shares 11.2K $0.88 Direct F1, F2, F5
transaction ENGN Stock Option (Right to Buy) Award +9.02K 9.02K Jan 11, 2016 Common Shares 9.02K $0.88 Direct F1, F2, F6
transaction ENGN Stock Option (Right to Buy) Award +3.19K 3.19K Jun 15, 2017 Common Shares 3.19K $0.88 Direct F1, F2, F7
transaction ENGN Stock Option (Right to Buy) Award +4.12K 4.12K Mar 16, 2018 Common Shares 4.12K $0.88 Direct F1, F2, F8
transaction ENGN Stock Option (Right to Buy) Award +12K 12K Dec 14, 2020 Common Shares 12K $0.88 Direct F1, F2, F9
transaction ENGN Stock Option (Right to Buy) Award +14.2K 14.2K Aug 20, 2021 Common Shares 14.2K $0.88 Direct F1, F2, F10
transaction ENGN Stock Option (Right to Buy) Award +12K 12K Aug 20, 2021 Common Shares 12K $0.88 Direct F1, F2, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 31, 2023 (the "Closing Date"), the parties to the Business Combination Agreement, dated as of May 16, 2023 (as amended, the "Business Combination Agreement"), by and among Forbion European Acquisition Corp., a Cayman Islands exempted company and a special purpose acquisition corporation ("FEAC"), enGene Inc., a corporation incorporated under the laws of Canada ("enGene"), and enGene Holdings Inc. (the "Issuer" or "New enGene"), completed the transactions contemplated thereby, pursuant to which (i) each share of FEAC was exchanged on a one for one basis for a share of New enGene, and (ii) each share of enGene was exchanged for 0.1804799669 shares of New enGene, and each of FEAC and enGene became wholly-owned subsidiaries of New enGene. The transactions contemplated by the Business Combination Agreement are referred to herein as the "Business Combination".
F2 Pursuant to the terms of the Business Combination, the shareholders of enGene received 0.1804799669 common shares of the Issuer ("Common Shares") for each share of enGene held by them immediately prior to the Closing Date. Upon the Closing of the Business Combination, all outstanding enGene options were assumed by New enGene. enGene options that were issued or available to be issued as of May 16, 2023 were accelerated and become vested and exercisable (if not previously vested and exercisable). The issuance of the securities to the Reporting Person was approved by the Issuer's board of directors in the manner contemplated by Rule 16b-3 under the Securities Exchange Act of 1934, as amended.
F3 Reflects Common Shares acquired pursuant to the Business Combination.
F4 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 667 common shares of enGene.
F5 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 62,000 common shares of enGene.
F6 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 50,000 common shares of enGene.
F7 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 17,668 common shares of enGene.
F8 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 22,848 common shares of enGene.
F9 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,667 common shares of enGene.
F10 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 78,712 common shares of enGene.
F11 This option is fully vested and exercisable. This option was received in the Business Combination in exchange for an option to purchase 66,500 common shares of enGene.